What is the 13F Pro Quality Score for LFVN?

13F Pro ranks Lifevantage Corp (LFVN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LFVN's current score at https://13fpro.ai/research/LFVN (free sign-up required for the full ranking).

Which hedge funds own the most LFVN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of LFVN include CAPITAL MANAGEMENT /VA, RENAISSANCE TECHNOLOGIES, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/LFVN as soon as new 13F filings post.

Where does 13F Pro source LFVN data?

All Lifevantage Corp fundamentals and ownership data come directly from SEC EDGAR. Lifevantage Corp files with the SEC under CIK 849146. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LFVN in?

Lifevantage Corp (LFVN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LFVN research updated on 13F Pro?

LFVN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Lifevantage Corp(LFVN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 849146 LFVN stock profile & AI dashboard →

13F Pro Quality Score

49.6/100

Rank #1,502 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

32.6/100

Profitability

53.8/100

Balance Sheet

86.6/100

Earnings Quality

86.3/100

Free Cash Flow

42.1/100

Institutional Flow

63.5/100

Revenue Scale

24.4/100

Dilution Risk

37.4/100

LFVN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Lifevantage Corp (LFVN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LFVN at 49.6/100 on a 32-signal composite quality model, placing it at rank #1,502 of 2,879 stocks — the bottom half of the AI-ranked universe. LFVN scores in the top quartile across balance sheet strength (86.6), earnings quality (86.3). Areas of concern include revenue scale (24.4) and revenue growth (32.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 37.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), Lifevantage Corp reports quarterly revenue of $43.7M, net income of $1.4M, an operating margin of 3.8%. Top institutional holders of LFVN by reported 13-F value include CAPITAL MANAGEMENT /VA, RENAISSANCE TECHNOLOGIES, BlackRock,, based on the most recent SEC filings. LFVN trades on the Nasdaq exchange and files with the SEC under CIK 849146. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LFVN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lifevantage Corp directly from SEC EDGAR. Lifevantage Corp's 13F Pro composite quality score has ranged between 8 and 56 since 2021, currently 49.6 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Lifevantage Corp

Quirks, history, and lore behind LFVN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in Utah.
2
The Numbers
Annual revenue in the range of roughly $200 million, with a direct-sales network doing most of the heavy lifting — no store shelves required.
3
The History
Founded in the early 2000s, the company built its business around a single flagship antioxidant supplement before slowly expanding its product line.
4
The Secret
Its products lean hard into Nrf2 activation — a cellular pathway that sounds like a sci-fi plot device but is a real area of nutrigenomics research.
5
The Lore
Its best-known product, Protandim, got a burst of fame from a ABC News segment and has been cited in peer-reviewed studies, which is not something most supplement companies can say.
6
The Giveaway
A Utah-based MLM-style wellness company whose flagship Protandim Nrf2 Synergizer promises to fight oxidative stress — and whose ticker literally spells out "life advantage."

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q3 2026

$43.7M

Net Income

Q3 2026

$1.4M

Free Cash Flow

Q3 2026

$4.0M

Operating Margin

Q3 2026

3.8%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+14.2% YoY

$228.5MFY 2025

FY22 $206.4MFY23 $213.4MFY24 $200.2MFY25 $228.5M

Net Income

+233.8% YoY

$9.8MFY 2025

FY22 $3.1MFY23 $2.5MFY24 $2.9MFY25 $9.8M

Operating Income

+181.6% YoY

$12.2MFY 2025

FY22 $7.6MFY23 $4.3MFY24 $4.3MFY25 $12.2M

EPS (Diluted)

+226.1% YoY

$0.75FY 2025

FY22 $0.24FY23 $0.20FY24 $0.23FY25 $0.75

Total Assets

+19.3% YoY

$72.0MFY 2025

FY22 $70.7MFY23 $66.1MFY24 $60.3MFY25 $72.0M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

-2.6% YoY

$11.9MFY 2025

FY22 $8.0MFY23 $6.8MFY24 $12.2MFY25 $11.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$228.5M +14.2%	$200.2M -6.2%	$213.4M +3.4%	$206.4M -6.3%	$220.2M -5.5%	$232.9M
Net Income	$9.8M +233.8%	$2.9M +15.6%	$2.5M -18.6%	$3.1M -75.8%	$12.9M +11.6%	$11.5M
Operating Income	$12.2M +181.6%	$4.3M +1.7%	$4.3M -43.8%	$7.6M -57.0%	$17.6M +13.9%	$15.5M
EPS (Diluted)	$0.75 +226.1%	$0.23 +15.0%	$0.20 -16.7%	$0.24 -73.3%	$0.90 +13.9%	$0.79
Total Assets	$72.0M +19.3%	$60.3M -8.8%	$66.1M -6.5%	$70.7M -10.2%	$78.7M +33.7%	$58.9M
Total Debt	—	—	—	—	—	$0.00
Operating Cash Flow	$11.9M -2.6%	$12.2M +78.6%	$6.8M -14.2%	$8.0M -51.1%	$16.3M -11.2%	$18.3M

AI Insight: LFVN Financial Trends

Revenue has declined 37% from Q4 2024 peak of $68M to $44M in Q1 2026, while profitability has collapsed.

• Revenue contracted from $68M in Q4 2024 to $44M in Q1 2026, a 35% decline over five quarters.

• Net income fell from $3M in Q4 2024 to $1M in Q1 2026; operating income halved from $3M to $2M.

• Operating cash flow volatile—positive $9M in Q4 2024, negative $2M in Q3 2025, recovered to $5M in Q1 2026.

⚠ Operating margin deteriorated from 4.4% in Q4 2024 to 4.5% in Q1 2026 amid sharp revenue erosion.

⚠ Q4 2025 net income and operating income both hit zero—first break-even quarter in dataset.

AI Insight: LFVN Ratio Trends

Operating margin collapsed to 1.0% in Q4 2025, dragging TTM profitability to lows; ROIC fell 73% from Q1 2025 peak of 47.7% to 20.1% in TTM.

• Operating margin deteriorated from 6.9% in Q1 2025 to 1.0% in Q4 2025, a 580bp cliff; TTM OpMargin now 3.4%.

• Net profit margin compressed from 5.9% in Q1 2025 to 0.6% in Q4 2025; TTM NPM at 2.9%, near multi-quarter low.

• ROIC halved from 47.7% in Q1 2025 to 20.1% in TTM; Q4 2025 saw extreme deterioration to 5.9%.

⚠ Q4 2025 profitability metrics (OpMargin 1.0%, NPM 0.6%, ROA 1.8%) suggest material operational disruption or write-down event.

⚠ TTM recovery in Q1 2026 (OpMargin 3.8%, NPM 3.1%) modest; Q4 2025 weakness persists as meaningful quarterly headwind.

Get alerted when LFVN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Lifevantage Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LFVN

CAPITAL MANAGEMENT CORP /VA
$10.5M2,441,919 sh
RENAISSANCE TECHNOLOGIES LLC
$3.7M867,704 sh
BlackRock, Inc.
$3.3M769,698 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.9M429,422 sh
DIMENSIONAL FUND ADVISORS LP
$1.2M276,196 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.1M261,192 sh
ENVESTNET ASSET MANAGEMENT INC
$946.8K219,162 sh
GOLDMAN SACHS GROUP INC
$799.7K185,114 sh
STATE STREET CORP
$722.1K167,143 sh
AQR CAPITAL MANAGEMENT LLC
$674.3K156,096 sh

Fund	Value	Shares
CAPITAL MANAGEMENT CORP /VA	$10.5M	2,441,919
RENAISSANCE TECHNOLOGIES LLC	$3.7M	867,704
BlackRock, Inc.	$3.3M	769,698
VANGUARD CAPITAL MANAGEMENT LLC	$1.9M	429,422
DIMENSIONAL FUND ADVISORS LP	$1.2M	276,196
GEODE CAPITAL MANAGEMENT, LLC	$1.1M	261,192
ENVESTNET ASSET MANAGEMENT INC	$946.8K	219,162
GOLDMAN SACHS GROUP INC	$799.7K	185,114
STATE STREET CORP	$722.1K	167,143
AQR CAPITAL MANAGEMENT LLC	$674.3K	156,096

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LFVN on your watchlist

Track score changes the day Lifevantage Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LFVN a good stock to buy?

13F Pro's AI-powered analysis of Lifevantage Corp (LFVN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LFVN are available on the LFVN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LFVN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LFVN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Lifevantage Corp's investment landscape.